✦ LIBER ✦

196: Cost-Effectiveness of Aliskiren as Add on to Losartan and Optimal Antihypertensive Therapy in Patients with Type 2 Diabetes, Hypertension and Nephropathy in the UK Setting

✍ Scribed by James L. Palmer; Veronica C. Munk; Robert W. Kotchie; Gabor Vincze; Alan Charney; Daniel M.D. Tucker; Lieven Annemans

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV34 THE COST-EFFECTIVENESS OF ALISKIRE

✍ JL Palmer; VC Munk; R Kotchie; G Vincze; Charney k; D Tucker; L Annemans 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

PCV72 COST-EFFECTIVENESS ANALYSIS OF ADD

✍ P Kutscherauer; R Kodym; D Bartaskova 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

PDB19 ESTIMATING THE COST EFFECTIVENESS

✍ A Brennan; M Gillett; A Duenas 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PDB62 COST-UTILITY ANALYSIS OF SAXAGLIPT

✍ FG Eliaschewitz; E Asano; ME Nita; R Rached; BM Donato 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Cost-Effectiveness of Switching Patients

✍ Li Yang; Torsten Christensen; Fengyu Sun; Jinghua Chang 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB

PDB33 EVALUATING THE COST-EFFECTIVENESS

✍ L. Yang; A.L. Lay; J.H. Chang 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB